



31 AUGUST 2019

#### **PROFILE**

Objective To achieve long-term capital

growth in excess of the capital return of the FTSE World index.

Benchmark FTSE World index

Sector Global Launch 1999

## **PORTFOLIO**

# **Region allocation**

	31 Jul	31 Aug
Europe	44.5%	41.9%
North America	38.5%	39.6%
Asia Pacific ex Japan	7.8%	7.8%
Emerging Markets	7.8%	7.6%
Cash	1.4%	3.1%

# **Top 10 holdings** (39.7% of total portfolio)

Visa	4.6%
Automatic Data Processing	4.5%
AIA	4.1%
ResMed	4.0%
Microsoft	4.0%
Linde	4.0%
CSL	3.7%
Straumann	3.7%
Masimo	3.6%
Coloplast	3.5%
Number of holdings	32
Number of countries	15
Active share <sup>†</sup>	93.5%

# Key facts

Total assets	£245.4m
Share price (p)	290.0
Net asset value per share (p)	293.1
Discount (premium)	1.0%
Historic net vield <sup>‡</sup>	1 4%

#### **PERFORMANCE**

#### Cumulative performance over periods to 31 August 2019

	One month	Three months	Six months	One year	Three years	Five years
Share price	(6.0%)	5.2%	14.5%	12.5%	47.6%	85.1%
NAV	(2.0%)	8.0%	16.4%	12.3%	47.8%	86.1%
Benchmark	(1.7%)	8.3%	12.9%	7.1%	42.7%	84.6%

# 12-month performance

	To end <b>Q2 2019</b>	To end <b>Q2 2018</b>	To end <b>Q2 2017</b>	To end <b>Q2 2016</b>	To end Q2 2015
Share price	18.9%	8.1%	22.1%	11.2%	9.5%
NAV	18.3%	8.5%	22.1%	11.3%	10.5%
Benchmark	10.4%	9.3%	22.9%	14.6%	9.9%

#### Past performance is not a guide to future returns.

Source: Martin Currie. The NAV basis used is cum-income in £. Please note prior to July 2017 the NAV basis used was ex-income NAV in £. Ex-income NAVs exclude current-year income, while cum-income NAVs include current-year income. These figures do not include the cost of buying and selling shares in an investment trust. If these were included, performance figures would be reduced.

Prior to 30 June 2011 the Company's benchmark was the FTSE All-Share index and the FTSE World index thereafter.

# **MANAGERS' COMMENTARY**

At the stock level, ResMed – the global leader in medical devices treating sleep apnea – was the strongest performer in the portfolio with the share price remaining strong after the company reported solid fourth-quarter numbers at the end of July. ResMed beat growth estimates, and guidance for next year was better than expected at the margin level. Consumer goods giant Unilever was another notable positive for the portfolio as was Automatic Data Processing, a US provider of human resources management software and services.

On the other side, the biggest drag on performance in August was UK financial services company Prudential. Despite a solid operating performance, the stock has struggled against the backdrop of some unfavourable macro developments including Brexit and US regulatory reform. Chinese internet platform Tencent also suffered following second-quarter results which were in line with expectations in terms of profits, but a little weak on revenue. Against a less-favourable Chinese macro environment, the results indicated a clear weakness in advertising. However, management commentary on its games segment was positive, especially as the second half of the year is expected to include some important new launches. Swedish lock manufacturer Assa Abloy was another notable negative.

In terms of portfolio activity, we sold Prudential. As well as the issues noted above, the conglomerate nature of the business – which groups together three fairly independent units (UK, US and Asia) – has proved to be a drag

rather than a benefit, as ongoing scepticism on the quality and the prospects of the US business has weighed on the group's overall valuation. Given our lower conviction against other held names, we decided to exit the position.



**Zehrid Osmani** 

<sup>†</sup>Source: Martin Currie and FIS APT. Active share is a measure of the percentage difference between the portfolio holdings and the index constituents.

<sup>&</sup>lt;sup>‡</sup>Source for historic yield: Martin Currie as at 31 August 2019. The historic yield reflects dividends declared for the previous financial year as a percentage of the mid-market share price, as at the date shown. Investors may be subject to tax on their dividends.

#### **CAPITAL STRUCTURE**

Ordinary shares 83,742,150

## **BOARD OF DIRECTORS**

Neil Gaskell (chairman) Marian Glen Gary Le Sueur Gillian Watson

# **KEY INFORMATION**

Year end 31 January
Annual general meeting June

Interim dividends paid October, January, April, July

Investment management fee 0.40% Ongoing charge as at 0.63% 31 January 2019§ 0.63%

Performance fee 12.5% of the outperformance of the

benchmark above 1%. Capped at 1% of the NAV. The first performance review period is to 31 January 2020, with performance fee opportunity annual thereafter. For more detail please refer to

the website.

TIDM code MNP
Reuters code MNP.L
Sedol code 0537241

#### Net asset value and dividend history

As at 31 January	Share price	NAV per share	Discount/ (premium)	Dividend per share
2009	89.8p	93.1p	3.5%	3.50p
2010	113.5p	122.2p	7.1%	3.50p
2011	125.0p	135.5p	7.7%	3.50p
2012	129.0p	139.2p	7.3%	3.70p
2013	147.4p	152.6p	3.4%	3.90p
2014	156.5p	157.4p	0.6%	4.00p
2015	179.5p	178.6p	(0.5%)	4.10p
2016	173.0p	176.3p	1.9%	4.15p
2017	223.8p	224.0p	0.1%	4.20p
2018	247.0p	246.2p	(0.3%)	4.20p
2019	242.0p	245.9p	1.6%	4.20p

Past performance is not a guide to future returns.

#### **MANAGER'S BIOGRAPHY**

#### **Zehrid Osmani**

Zehrid joined Martin Currie from BlackRock where, during his ten years, he played a key part in building their successful European equity franchise. He held a number of senior roles at the company, including Head of European Research, with responsibility for a 23-strong team of analysts. In this role, he developed and implemented a fundamental research platform, demonstrating his strong understanding of equity research. Zehrid also managed a number of equity funds at BlackRock, with a specific focus on managing the team's unconstrained, high conviction, long term portfolios, driven by fundamental research.

#### **WEBSITE**

The Company has its own website at <a href="www.martincurrieglobal.com">www.martincurrieglobal.com</a> There you will find information on Martin Currie, daily share prices (and associated risks), and you can access regular videos by the manager.



# www.martincurrieglobal.com



Shareholder Communication Awards 2018



# IMPORTANT INFORMATION

This information is issued and approved by Martin Currie Investment Management Limited. It does not constitute investment advice. Market and currency movements may cause the capital value of shares, and the income from them, to fall as well as rise and you may get back less than you invested. Please note that, as the shares in investment trusts are traded on a stockmarket, the share price will fluctuate in accordance with supply and demand and may not reflect the value of underlying net asset value of the shares.

Depending on market conditions and market sentiment, the spread between purchase and sale price can be wide. As with all stock exchange investments the value of investment trust share purchases will immediately fall by the difference between the buying and selling prices, the bid-offer spread. The value of investments and the income from them may go down as well as up and is not guaranteed. An investor may not get back the amount originally invested.

The majority of charges will be deducted from the capital of the Company. This will constrain capital growth of the Company in order to maintain the income streams.

Martin Currie Investment Management Limited, registered in Scotland (no SC066107).

Registered office: Saltire Court, 20 Castle Terrace, Edinburgh EH1 2ES

Tel: 0808 100 2125 Fax: 0870 888 3035 www.martincurrie.com

This company is authorised and regulated by the Financial Conduct Authority. Please note that call to the above number may be recorded.

<sup>0.4%</sup> of the NAV of the Company per annum, calculated quarterly.

<sup>§</sup>Percentage of shareholders' funds. Management fee of 0.4% effective 1 February 2018